(NASDAQ: VRCA) Verrica Pharmaceuticals's forecast annual revenue growth rate of 201.97% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Verrica Pharmaceuticals's revenue in 2024 is $5,124,000.On average, 3 Wall Street analysts forecast VRCA's revenue for 2024 to be $1,059,021,594, with the lowest VRCA revenue forecast at $986,655,543, and the highest VRCA revenue forecast at $1,185,174,371. On average, 3 Wall Street analysts forecast VRCA's revenue for 2025 to be $3,323,493,628, with the lowest VRCA revenue forecast at $2,539,174,583, and the highest VRCA revenue forecast at $4,029,762,535.
In 2026, VRCA is forecast to generate $6,064,580,522 in revenue, with the lowest revenue forecast at $3,808,337,688 and the highest revenue forecast at $8,271,617,835.